Compare Five9 Inc (FIVN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Five9 Inc trades at $33.37 (market cap $2.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FIVN | TVTX | |
|---|---|---|
Market Cap | $2.47B | $5.02B |
Volume | 1,632,106 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $38.65 | $67.52 |
52-Week Low | $13.61 | $26.79 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $2.62B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.41, down 0.73% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent AI revenue surged 78% to $39M, now representing 15% of subscription revenue, driving investor optimism.
The outlook remains positive with analyst consensus at Buy (61%) and $34 price target, though current price exceeds consensus. Key risks include competitive CCaaS market pressure and insider selling activity. Revenue growth momentum and AI adoption provide upside potential, but valuation multiples remain elevated with P/E of 52 requiring sustained execution.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
